Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

被引：66

作者：

Demeter, LM

Shafer, RW

Meehan, PM

Holden-Wiltse, J

Fischl, MA

Freimuth, WW

Para, MF

Reichman, RC

机构：

[1] Univ Rochester, Infect Dis Unit, Sch Med & Dent, Rochester, NY 14642 USA

[2] Stanford Univ, Palo Alto, CA 94304 USA

[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

[4] Univ Miami, Miami, FL 33152 USA

[5] Pharmacia & Upjohn Inc, Kalamazoo, MI 49001 USA

[6] Ohio State Univ, Columbus, OH 43210 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 03期

关键词：

D O I：

10.1128/AAC.44.3.794-797.2000

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.

引用

收藏

页码：794 / 797

页数：4

相关论文

共 20 条

[1] COMPREHENSIVE MUTANT ENZYME AND VIRAL VARIANT ASSESSMENT OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE RESISTANCE TO NONNUCLEOSIDE INHIBITORS [J].

BYRNES, VW ;

SARDANA, VV ;

SCHLEIF, WA ;

CONDRA, JH ;

WATERBURY, JA ;

WOLFGANG, JA ;

LONG, WJ ;

SCHNEIDER, CL ;

SCHLABACH, AJ ;

WOLANSKI, BS ;

GRAHAM, DJ ;

GOTLIB, L ;

RHODES, A ;

TITUS, DL ;

ROTH, E ;

BLAHY, OM ;

QUINTERO, JC ;

STASZEWSKI, S ;

EMINI, EA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (08) :1576-1579

[2]

DeClercq E, 1996, MED RES REV, V16, P125, DOI 10.1002/(SICI)1098-1128(199603)16:2<125::AID-MED1>3.0.CO

[3]

2-2

[4] HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delaviridine [J].

Demeter, LM ;

Meehan, PM ;

Morse, G ;

Gerondelis, P ;

Dexter, A ;

Berrios, L ;

Cox, S ;

Freimuth, W ;

Reichman, RC .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 14 (02) :136-144

[5] U-90152, A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPLICATION [J].

DUEWEKE, TJ ;

POPPE, SM ;

ROMERO, DL ;

SWANEY, SM ;

SO, AG ;

DOWNEY, KM ;

ALTHAUS, IW ;

REUSSER, F ;

BUSSO, M ;

RESNICK, L ;

MAYERS, DI ;

LANE, J ;

ARISTOFF, PA ;

THOMAS, RC ;

TARPLEY, WG .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :1127-1131

[6] A MUTATION IN REVERSE-TRANSCRIPTASE OF BIS(HETEROARYL)PIPERAZINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 THAT CONFERS INCREASED SENSITIVITY TO OTHER NONNUCLEOSIDE INHIBITORS [J].

DUEWEKE, TJ ;

PUSHKARSKAYA, T ;

POPPE, SM ;

SWANEY, SM ;

ZHAO, JQ ;

CHEN, ISY ;

STEVENSON, M ;

TARPLEY, WG .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (10) :4713-4717

[7] Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor [J].

Esnouf, RM ;

Ren, JS ;

Hopkins, AL ;

Ross, CK ;

Jones, EY ;

Stammers, DK ;

Stuart, DI .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3984-3989

[8] The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities [J].

Gerondelis, P ;

Archer, RH ;

Palaniappan, C ;

Reichman, RC ;

Fay, PJ ;

Bambara, RA ;

Demeter, LM .

JOURNAL OF VIROLOGY, 1999, 73 (07) :5803-5813

[9] STANDARDIZATION OF SENSITIVE HUMAN-IMMUNODEFICIENCY-VIRUS COCULTURE PROCEDURES AND ESTABLISHMENT OF A MULTICENTER QUALITY ASSURANCE PROGRAM FOR THE AIDS CLINICAL-TRIALS GROUP [J].

HOLLINGER, FB ;

BREMER, JW ;

MYERS, LE ;

GOLD, JWM ;

MCQUAY, L .

JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (07) :1787-1794

[10] STANDARDIZED MICROTITER ASSAY FOR DETERMINATION OF SYNCYTIUM-INDUCING PHENOTYPES OF CLINICAL HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES [J].

JAPOUR, AJ ;

FISCUS, SA ;

ARDUINO, JM ;

MAYERS, DL ;

REICHELDERFER, PS ;

KURITZKES, DR .

JOURNAL OF CLINICAL MICROBIOLOGY, 1994, 32 (09) :2291-2294